Lone Peak Global Investors LLC Raises Stake in Becton, Dickinson and Company $BDX

Lone Peak Global Investors LLC grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.2% during the 2nd quarter, HoldingsChannel reports. The fund owned 156,130 shares of the medical instruments supplier’s stock after acquiring an additional 9,062 shares during the quarter. Becton, Dickinson and Company makes up 3.3% of Lone Peak Global Investors LLC’s investment portfolio, making the stock its 12th biggest position. Lone Peak Global Investors LLC’s holdings in Becton, Dickinson and Company were worth $23,627,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC boosted its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Becton, Dickinson and Company by 4.4% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after acquiring an additional 26,671 shares during the last quarter. Cooke & Bieler LP lifted its stake in shares of Becton, Dickinson and Company by 27.2% in the 4th quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock valued at $218,614,000 after acquiring an additional 240,673 shares during the last quarter. Northside Capital Management LLC boosted its holdings in Becton, Dickinson and Company by 18.3% during the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after acquiring an additional 9,494 shares during the period. Finally, Wealthfront Advisers LLC bought a new position in Becton, Dickinson and Company during the 2nd quarter worth approximately $2,567,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 9,105 shares of company stock valued at $1,590,208. Company insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BDX shares. Jefferies Financial Group reissued a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. UBS Group began coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. The Goldman Sachs Group lowered their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Finally, Bank of America raised their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $187.67.

Becton, Dickinson and Company Trading Down 0.5%

NYSE:BDX opened at $187.23 on Wednesday. The company has a 50-day moving average price of $167.95 and a 200-day moving average price of $160.37. The stock has a market cap of $51.59 billion, a price-to-earnings ratio of 56.39, a P/E/G ratio of 13.26 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.